Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines

(BUSINESS WIRE) -- Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient population.

Today, at the International Master Course on Aging Science (IMCAS) 2025 annual congress, Galderma will also host a first-of-its-kind masterclass on this topic with international aesthetics experts. Titled “Managing Facial Changes in Patients with Medication-Driven Weight-Loss”, the session will be the opportunity to discuss strategies for managing facial changes in this patient population in clinical practice.

While the rates and stages of adoption differ worldwide, the use of prescription weight loss medications is set to increase globally, with $100 billion sales globally forecasted by 2030, which will have a considerable impact on aesthetics for both patients and healthcare professionals³. With 62% of patients using glucagon-like peptide-1 (GLP-1) getting aesthetic treatment following a healthcare professional recommendation¹, there is a clear need for guidance on how to treat this new patient population.

First international consensus-based guidelines

Recognizing the significance and broad impact of prescription weight loss medications, Galderma commissioned the Delphi study to address the need for high-quality research in this area and help establish clinical guidelines for identifying and managing the unique needs of this patient population. This international, multidisciplinary study — incorporating patient interviews, market research, literature reviews, and insights from global experts with extensive experience in treating medication-driven weight loss patients — culminated in a global consensus on key criteria, expert perspectives, and treatment prioritization, all supported by real-world case studies². These novel consensus guidelines, submitted for publication as the first international consensus-based guidelines from global experts on how to treat this patient population, will be presented by Dr. Andreas Nikolis, during a focus session on “Rapid facial volume loss: causes and consequences” on January 31^st, 2025 in the Grand Amphi.

Additionally, Galderma has surveyed more than 1,000 male and female respondents using weight loss medications, aged between 25-65 across the United States, Brazil, Europe and the Middle East¹. The focus is understanding the anatomical and aesthetic impact of medication-driven weight loss on the skin, to help equip healthcare professionals to guide patients effectively along their weight loss and aesthetics journey, based on their unique needs.

Medication-driven weight loss can lead to a myriad of facial changes, from dry or dull skin to sagging and a gaunt, hollowed-out appearance, as well as alterations in facial structure and balance⁴. Nearly half (48%) of respondents report significant facial changes due to weight loss treatment¹. Menopausal women, in particular, experience higher levels of sagging skin, a slimmer face, and less radiant skin¹. Loose or sagging skin on the face and neck is often noted after some weight loss, with facial changes typically observed 3-6 months following treatment (45%), and sometimes as early as 1-2 months (28%)¹. These changes occur for several reasons: the loss of fat that typically stretches and cushions the skin, contributing to a youthful appearance, can lead to volume depletion and sagging¹. Additionally, the reduction of collagen, elastin, and other essential nutrients can affect skin quality, facial definition, and contouring¹.

60% of aesthetic users have undergone treatments to address these effects, while one third of aesthetic considerers would have taken additional measures to prevent skin changes if they had known about the effects on the skin prior to starting their weight loss journey¹. The data further reveals that a significant barrier to pursuing aesthetic treatments is the lack of education and information, affecting both current and potential aesthetic users, regardless of their geographical location or stage in the weight loss process¹. Further, more than 60% of patients experiencing medicine-driven weight loss show a strong interest in a dual-expertise service that integrates medical and aesthetic professionals to support them during their journey¹. These findings from Galderma’s research show that a new, holistic approach to weight loss planning could better support this specific patient population and the healthcare professionals who treat them.

Specifically, 48% of respondents in the study reported that they would undergo Sculptra^® treatment and 41% would undergo Restylane^® treatment, to address the changes experienced on their face as a result of weight loss treatment¹, demonstrating the need for different aesthetic treatments that address the impact on their skin throughout their weight loss journey.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

¹ Galderma MAC Research. 2024
² Nikolis A, Enright KM, Fabi S, Somenek M, Avelar L, Franco J, Haddad A, Angelo-Kathar M, Huang J, Safran T, Prygova I, Dayan S. Consensus statements on managing aesthetic needs in prescription medication-driven rapid weight loss patients: An international, multidisciplinary Delphi study. IMCAS 2025.
³ JP Morgan report. The increase in appetite for obesity drugs. November 2023
⁴ Humphrey CD, Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg. 2023;39:719-721

View source version on businesswire.com: https://www.businesswire.com/news/home/20250129028652/en/